Stifel Maintains Buy on Pulmonx, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise maintains a Buy rating on Pulmonx (NASDAQ:LUNG) but lowers the price target from $17 to $16.
October 31, 2024 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst Rick Wise maintains a Buy rating on Pulmonx but lowers the price target from $17 to $16, indicating a slight decrease in expected valuation.
The analyst's decision to maintain a Buy rating suggests continued confidence in Pulmonx's potential, but the lowered price target indicates a slight reduction in expected valuation. This could lead to neutral short-term price movement as the Buy rating offsets the impact of the lowered target.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100